As declared by Zhejiang Provincial Department of Science and Technology on November 26, 2021, R&D of COVID-19 Vaccine Targeted at Delta Variant has been incorporated into Key “Pioneer” R&D Projects of Zhejiang Province for the year of 2022. This project is initiated by Ningbo Rong’an Biological Pharmaceutical Co., Ltd through cooperation with Zhejiang Provincial Center for Disease Control and Prevention. As the collaborator, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is accelerating the development of inactivated COVID-19 vaccine targeted at Delta variant. So far, it has entered the non-clinical animal evaluation stage, including animal safety evaluation, immunogenicity evaluation and protection evaluation. In the near future, it will proceed with rolling submission of relevant information to Center for Drug Evaluation (CDE), NMPA.